Guidant to take $14 million charge on ICD (implantable cardioverter defibrillator) defect
This article was originally published in Clinica
Executive Summary
Guidant announced last week that it would take a $14 million pre-tax charge in the first quarter, because of a problem with its first generation implantable cardioverter defibrillators (ICDs).